News

MercadoLibre posted a strong 50% YoY revenue jump in Q2, with fintech monthly active users climbing to 88 million—a sign that its digital payments push is gaining real traction across Latin America. The company is showing the growth trajectory investors want to see post-pandemic, though the broader question is whether this pace can sustain as retail spending normalises. Australian investors with LatAm exposure or holding MELI should monitor whether this momentum holds into H2, as fintech adoption in emerging markets remains volatile.

SpaceX's earnings guidance suggests the company plans to offer wireless services using satellite technology, bypassing traditional telecom infrastructure. This threatens the competitive moat of AT&T, Verizon, and T-Mobile, which rely on expensive ground networks—hence the sell-off. For Australian investors, this signals longer-term disruption in telecom, though Telstra, Optus and Vodafone remain less exposed given Australia's geography and regulatory framework. The real threat emerges if SpaceX's satellite broadband actually delivers reliable, low-cost mobile coverage at scale.

Australia's virtual power plant (VPP) rollout is facing adoption headwinds, with households reluctant to participate despite having battery systems already installed. This matters because VPPs are critical to grid stability and energy policy ambitions—they reduce peak demand pressure, defer expensive infrastructure upgrades, and support renewable integration. If take-up remains weak, utilities and grid operators miss out on distributed energy resources, potentially pushing costs onto non-participants and slowing the energy transition timeline.

SolarEdge Technologies has seen its stock plunge roughly 25% following a revenue guidance miss, with weakness in European markets cited as the primary culprit—offsetting any gains from AI-related developments. This matters because SolarEdge is a major player in solar inverters and energy management, and European softness signals broader headwinds in the renewable energy transition, particularly as subsidies or demand dynamics shift. Australian investors should watch whether this indicates a slowdown in global solar capex spending, which could ripple through local renewable energy and infrastructure stocks.

Trump's administration has issued $100bn in tariff refunds—roughly 60% of total tariff revenue collected—in what's being called 'Liberation Day'. This represents a significant policy reversal that removes cost pressures on US importers and manufacturers, likely boosting corporate margins and consumer prices downward. For Australian investors, this signals a softer US inflation outlook, which could delay Fed rate cuts and support tech stocks heavily exposed to US tariff policy; ASX-listed companies with US supply chains (consumer goods, electronics retailers) may see margin relief.

AstraZeneca's apparent abandonment of preliminary takeover talks with Bristol Myers Squibb has created volatility in both stocks, with AZN initially dropping 9% on deal speculation before recovering on reports the discussions have ceased. The lack of clarity from either company about whether talks were serious or exploratory leaves shareholders and markets guessing about strategic direction and deal likelihood. Australian investors holding pharma exposure should monitor both companies' next earnings calls and formal statements for clarity on M&A intentions and pipeline strategy, as large pharmaceutical consolidation can materially affect sector valuations and competition dynamics.

Novo Nordisk, which revolutionized the GLP-1 weight-loss drug market with Ozempic and Wegovy, has lost market leadership to US rival Eli Lilly. The Danish pharma giant faces competitive pressure from Lilly's Mounjaro (tirzepatide) which is proving more effective and popular, partly due to supply constraints and manufacturing challenges at Novo. This shift has material implications for Novo's growth trajectory and profitability—GLP-1 drugs represent its highest-margin revenue streams. For Australian investors, Novo Nordisk is a significant healthcare holding via local superannuation and managed funds; weakening competitive position could pressure share performance, though the broader GLP-1 market remains massive and growing globally.

US services sector momentum remains solid in July, suggesting economic resilience despite earlier manufacturing weakness—but rising input costs add inflation pressure that could influence Fed policy. For Australian investors, strong US services activity supports global demand and the USD, which typically lifts commodity prices and benefits ASX resource stocks, though persistent cost pressures may keep the Fed in tightening mode longer than hoped. Watch for whether services pricing power translates into wage-price spiral concerns at the Fed's next decision.

The US economy expanded solidly in July, but persistent inflation and supply-chain constraints are forcing companies to moderate hiring despite strong demand. This creates a policy dilemma for the Federal Reserve: growth remains robust but labour market weakness could justify rate cuts. For Australian investors, this matters because a slowdown in US hiring could dampen global growth and pressure commodity prices, while also influencing the Fed's interest-rate trajectory—which affects AUD strength and ASX valuations, particularly in export-dependent sectors.

The federal government's first home buyer scheme—designed to help owner-occupiers into the market with just 5% deposits—is being gamed by high-income earners who convert properties into investments and by borrowers well above the intended income cap. This defeats the scheme's policy intent and increases financial risk: borrowers with minimal equity are more vulnerable to default if rates rise, while investment properties reduce stock available for genuine owner-occupiers. For Australian investors, this signals potential policy tightening ahead as the government faces political pressure to tighten eligibility criteria, which could dampen property demand and mortgage growth for the major banks.

Galaxy Digital, a major crypto-focused investment firm, reported an $85 million net loss in Q2 as falling cryptocurrency prices squeezed profitability—a sign that digital asset volatility is weighing on professional crypto operators. The revenue miss versus Wall Street expectations suggests the broader crypto rally may not be translating into sustained business growth for the sector. Australian investors exposed to crypto-linked stocks or considering crypto positions should note this as a reality check: even professional players are struggling with market timing and volatility, so retail investors should be cautious about speculative positioning in this space.

AMD reported earnings that failed to excite the market despite meeting expectations, with the key disappointment being guidance on profit margins—a critical metric for semiconductor firms. The stock weakness reflects a broader pattern where investors are pricing in slowing AI demand and tighter profitability across the chip sector. For Australian investors, this matters because AMD is a major portfolio holding in many tech-heavy ETFs, and semiconductor weakness can signal broader tech and growth concerns that ripple through the ASX 200.

Texas has effectively paused 474 GW of data center projects by ordering a regulatory audit of all new grid connections, targeting Bitcoin miners and AI infrastructure operators. This is significant because Texas hosts roughly 40% of US Bitcoin mining hash rate and has been a hub for energy-intensive AI compute due to cheap power. The freeze could redirect capital toward other jurisdictions, pressure crypto mining margins in the near term, and signal broader regulatory friction around energy-intensive AI deployments—a concern already present in Australia given our tight grid capacity and climate commitments.

US private sector job creation stumbled in July with just 44,000 new hires—well below expectations—signalling cooling labour demand. This matters because the ADP report is a key leading indicator for the monthly US jobs report and can influence Federal Reserve thinking on rate cuts; weak labour data typically strengthens the case for monetary easing. For Australian investors, softer US employment reduces recession risk but also suggests slower global growth ahead, which could weigh on commodity prices and ASX earnings given our heavy export exposure.

U.S. private sector job creation slowed significantly to just 44,000 in July, the weakest in six months, signalling a cooling labour market. This data is important because it suggests economic momentum may be fading faster than expected—likely to influence Fed rate-cut decisions at upcoming meetings. For Australian investors, weaker U.S. employment typically supports rate-cut bets, which could strengthen the AUD and lift local equity markets, particularly ASX sectors sensitive to global growth like technology and consumer stocks.

Uber beat Q2 profit expectations and reported strong growth in rides and food deliveries, suggesting resilient consumer spending despite economic headwinds. However, the share price decline despite earnings growth suggests investors are either pricing in higher expectations or concerned about forward guidance—watch for commentary on margin pressures and competitive intensity. For Australian investors, Uber's performance is a bellwether for consumer discretionary spending and gig economy health in developed markets.

Eli Lilly reported a 48% revenue increase driven by stronger-than-expected demand for its GLP-1 drugs Mounjaro and Zepbound, signalling continued market growth in the obesity and diabetes treatment space. This result underscores the blockbuster potential of GLP-1 therapeutics and validates the sector's expansion beyond initial forecasts, though it also highlights intense competition as other pharma players like Novo Nordisk scale similar offerings. For Australian investors, this strengthens the outlook for healthcare and pharmaceutical stocks, particularly those with exposure to metabolic disease treatments, and may influence how the ASX's healthcare sector performs relative to broader markets.

Eli Lilly delivered a strong earnings beat with $23B in revenue, driven by surging demand for its GLP-1 drugs Mounjaro (diabetes) and Zepbound (weight loss), which collectively saw volume grow 60% year-on-year. This result reflects the ongoing blockbuster momentum in the obesity and diabetes treatment class, where Lilly competes with Novo Nordisk—a competitive dynamic that's reshaping pharma valuations globally. For Australian investors, this signals sustained strength in the obesity-drug sector and validates the broader healthcare opportunity, though it also highlights Lilly's execution risk if demand eventually normalises.

CVS Health beat Q2 earnings expectations and raised its full-year 2026 guidance, signalling operational resilience in the US healthcare and pharmacy sector. This is positive for the broader healthcare space, though CVS is primarily US-listed and has limited direct ASX exposure. Australian investors with exposure to US healthcare or pharmacy benefit managers via ETFs or direct holdings should note the positive momentum, though the real earnings power and margin sustainability will depend on detailed commentary around PBM margins, which have faced regulatory scrutiny.

The FAO's warning of rising food prices signals persistent inflationary pressure globally, which could complicate central banks' efforts to control inflation and may delay rate cuts. For Australian investors, this matters because rising food costs feed into CPI data that influences RBA policy, and it supports commodity prices—particularly for agricultural exports where Australia is a major producer. Watch for upcoming CPI prints and any RBA commentary on food-driven inflation.